Type:5ml drop
Generic Name:Lomefloxacin 0.3% Eye or Ear prep
Manufacturer:Apex Pharma Ltd.
Price:৳60.00
Otitis media, Bacterial Conjunctivitis, Otitis externa
Ophthalmic Bacterial conjunctivitis Adults At the beginning of therapy on day 1: Instill 5 drops into the conjunctival sac within 20 minutes. Thereafter, until day 7-9: Instill 1 drop 3 times daily into the conjunctival sac. Otic/Aural Otitis externa 10 drops (0.5 mL, 1.5 mg ofloxacin) instilled into the affected ear once daily for 7 days. Chronic Suppurative Otitis Media with perforated tympanic membranes: 10 drops (0.5 mL, 1.5 mg ofloxacin) instilled into the affected ear twice daily for 14 days.
Ophthalmic Bacterial conjunctivitis Adults At the beginning of therapy on day 1: Instill 5 drops into the conjunctival sac within 20 minutes. Thereafter, until day 7-9: Instill 1 drop 3 times daily into the conjunctival sac. Otic/Aural Otitis externa For patients 13 years and older: 10 drops (0.5 mL, 1.5 mg ofloxacin) instilled into the affected ear once daily for 7 days. Acute Otitis Media (1 to 12 years old) with tympanostomy tubes is: 5 drops (0.25 mL, 0.75 mg ofloxacin) instilled into the affected ear twice daily for 10 days. Chronic Suppurative Otitis Media with perforated tympanic membranes: 12 years and older: 10 drops (0.5 mL, 1.5 mg ofloxacin) instilled into the affected ear twice daily for 14 days.
Lomefloxacin is contraindicated in patients with a history of hypersensitivity to Lomefloxacin, quinolone or any other components of this product.
Lomefloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
Long term treatment with antibiotics may enhance development of secondary fungal infections or may support growth of non-susceptible bacteria. Contact lenses should not be worn in the presence of infectious eye diseases and the product should not be instilled while wearing contact lenses. During prolonged use, it is recommended that physicians conduct periodic examinations of the eye, including measurement of the intraocular pressure.
Mild, transient sensation of burning, irritation or pain may be experienced on instillation.
Reduced bioavailability with sucralfate, antacids containing magnesium or aluminium, vitamin or mineral supplements containing iron. Increased serum levels with cimetidine. Potential increase in serum levels of ciclosporin. Renal elimination reduced with probenecid. Potentially Fatal: Increased risk of ventricular arrhythmias with class IA (quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmic agents.